Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Authors
Keywords
Survivin cancer therapeutics, survivin, BIRC5, Mcl-1, XIAP, cIAP2, MdmX, YM155, FL118, survivin immunotherapy
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-22
DOI
10.1186/s13046-019-1362-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine–Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin
- (2019) Yue Cao et al. ACS Applied Materials & Interfaces
- RNAi therapeutic and its innovative biotechnological evolution
- (2019) Yuhua Weng et al. BIOTECHNOLOGY ADVANCES
- An engineered mouse embryonic stem cell model with survivin as a molecular marker and EGFP as the reporter for high throughput screening of embryotoxic chemicals in vitro
- (2019) Ru Zang et al. BIOTECHNOLOGY AND BIOENGINEERING
- In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models
- (2019) Qi Weng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma
- (2019) Lisa C. Holthof et al. HAEMATOLOGICA
- Survivin at a glance
- (2019) Sally P. Wheatley et al. JOURNAL OF CELL SCIENCE
- SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.
- (2019) Manmeet Singh Ahluwalia et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma
- (2019) Hiroaki Shima et al. CANCER SCIENCE
- An Inhibitor of the Interaction of Survivin with Smac in Mitochondria Promotes Apoptosis
- (2019) Seong‐Hyun Park et al. Chemistry-An Asian Journal
- Uptake and efflux of FL118 and two FL118 derivatives in 3D cell model
- (2019) Leilei Zhou et al. CYTOTECHNOLOGY
- A direct interaction between survivin and myosin II is required for cytokinesis
- (2019) Aryeh Babkoff et al. JOURNAL OF CELL SCIENCE
- High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager
- (2019) Nobuyuki Kurosawa et al. Scientific Reports
- Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
- (2019) Shuhei Suzuki et al. Cancers
- Sensitization of colorectal cancer cells to irinotecan by the Survivin inhibitor LLP3 depends on XAF1 proficiency in the context of mutated p53
- (2018) Christian Steigerwald et al. ARCHIVES OF TOXICOLOGY
- miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin
- (2018) Meng Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma
- (2018) Haisen Yin et al. CANCER LETTERS
- Survivin -targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer
- (2018) Hui Lyu et al. CANCER LETTERS
- Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor GrowthIn Vivo
- (2018) Robert A. Fenstermaker et al. CLINICAL CANCER RESEARCH
- Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors
- (2018) Qinghui Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors
- (2018) SeongJu Yun et al. INTERNATIONAL JOURNAL OF CANCER
- FL118, a novel camptothecin analogue, suppressed migration and invasion of human breast cancer cells by inhibiting epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway
- (2018) Zhihong Yang et al. BioScience Trends
- Additive polyplexes to undertake siRNA therapy against CDC20 and survivin in breast cancer cells
- (2018) Manoj B Parmar et al. BIOMACROMOLECULES
- miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway
- (2018) Baojin Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
- (2018) Xiang Ling et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes
- (2018) Fanny Onodi et al. Frontiers in Oncology
- Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis
- (2017) Xinyan Chen et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
- (2017) Rina M. Mbofung et al. Nature Communications
- Magnetic Cationic Amylose Nanoparticles Used to Deliver Survivin-Small Interfering RNA for Gene Therapy of Hepatocellular Carcinoma In Vitro
- (2017) Zhuo Wu et al. Nanomaterials
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
- (2016) Robert A. Fenstermaker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Finally, An Apoptosis-Targeting Therapeutic for Cancer
- (2016) C. M. Croce et al. CANCER RESEARCH
- Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors
- (2016) Jing Qi et al. CANCER RESEARCH
- A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma
- (2016) Kyriakos P. Papadopoulos et al. LEUKEMIA & LYMPHOMA
- Disruption of protein–protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target – survivin
- (2016) Sailu Sarvagalla et al. RSC Advances
- Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer
- (2016) Hong Yan Liu et al. Scientific Reports
- The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA
- (2016) Caina Xu et al. Biomaterials Science
- Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs
- (2015) Y K Lee et al. CANCER GENE THERAPY
- Piperine derivatives as potential inhibitors of Survivin: An in silico molecular docking
- (2015) Elham Sattarinezhad et al. COMPUTERS IN BIOLOGY AND MEDICINE
- Adeno-associated virus mediated gene transfer of Shepherdin inhibits gallbladder carcinoma growth in vitro and in vivo
- (2015) Aijun Zhu et al. GENE
- New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
- (2015) David Westover et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
- (2015) David Westover et al. Molecular Cancer
- Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer
- (2015) G. Salzano et al. MOLECULAR CANCER THERAPEUTICS
- Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties
- (2015) Min Xiao et al. PLoS One
- Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
- (2015) Neil L Berinstein et al. OncoImmunology
- Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
- (2014) Michael R. Clemens et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
- (2014) Volker Lennerz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX
- (2014) X. Ling et al. CANCER RESEARCH
- Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study
- (2014) Ronald Natale et al. Journal of Thoracic Oncology
- Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D
- (2014) Małgorzata Krześniak et al. MECHANISMS OF AGEING AND DEVELOPMENT
- Optimization of irinotecan chronotherapy with P-glycoprotein inhibition
- (2014) Elisabeth Filipski et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma
- (2014) J. K. Shoeneman et al. Veterinary and Comparative Oncology
- A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
- (2014) Ragini Kudchadkar et al. Cancer Medicine
- A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
- (2013) R. J. Kelly et al. ANNALS OF ONCOLOGY
- SF002-96-1, a new drimane sesquiterpene lactone from anAspergillusspecies, inhibits survivin expression
- (2013) Silke Felix et al. Beilstein Journal of Organic Chemistry
- Design, synthesis and biological studies of Survivin Dimerization Modulators that prolong mitotic cycle
- (2013) Somsundaram N. Chettiar et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer
- (2013) G. Salzano et al. CANCER LETTERS
- A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer
- (2013) Paweł Wiechno et al. EUROPEAN UROLOGY
- Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma
- (2013) Subrata K. Ghosh et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
- (2013) Harry P. Erba et al. INVESTIGATIONAL NEW DRUGS
- Withanone as an inhibitor of survivin: A potential drug candidate for cancer therapy
- (2013) Varsha P. Wadegaonkar et al. JOURNAL OF BIOTECHNOLOGY
- A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
- (2013) Elizabeth A. Raetz et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer
- (2013) D. T. Martin et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Activity of FL118, a Survivin, Mcl-1, XIAP, and cIAP2 Selective Inhibitor, Is Highly Dependent on Its Primary Structure and Steric Configuration
- (2013) Jiuyang Zhao et al. MOLECULAR PHARMACEUTICS
- Sepantronium Bromide (YM155) induces disruption of the ILF3/p54nrb complex, which is required for survivin expression
- (2012) Tomohiro Yamauchi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response
- (2012) Trevor G. Glaros et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
- (2012) Jürgen C. Becker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
- (2012) Hidekazu Kameshima et al. CANCER SCIENCE
- Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin-Ran Protein Complex
- (2012) H. Guvenc et al. CLINICAL CANCER RESEARCH
- MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity
- (2012) Asao Sakai et al. Journal of Thoracic Oncology
- Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
- (2012) Naoto Nakamura et al. MOLECULAR & CELLULAR PROTEOMICS
- YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
- (2012) Young-Soon Na et al. PLoS One
- Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients
- (2012) Azeem Saleem et al. Theranostics
- Redox-Active Polymer Microcapsules for the Delivery of a Survivin-Specific siRNA in Prostate Cancer Cells
- (2011) Alisa L. Becker et al. ACS Nano
- A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
- (2011) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263
- (2011) Haikuo Tang et al. BIOCHEMICAL PHARMACOLOGY
- Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia
- (2011) E. Park et al. BLOOD
- A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
- (2011) Bruce D. Cheson et al. CANCER
- Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients
- (2011) Hidekazu Kameshima et al. CANCER SCIENCE
- Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models
- (2011) Kentaro Yamanaka et al. CLINICAL CANCER RESEARCH
- Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
- (2011) Melanie Widenmeyer et al. INTERNATIONAL JOURNAL OF CANCER
- Antisense Inhibition of Survivin Expression as a Cancer Therapeutic
- (2011) R. A. Carrasco et al. MOLECULAR CANCER THERAPEUTICS
- Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line
- (2011) Hamidreza Montazeri Aliabadi et al. MOLECULAR PHARMACEUTICS
- Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin
- (2011) A Berezov et al. ONCOGENE
- Association of Long-term Administration of the Survivin mRNA-Targeted Antisense Oligonucleotide LY2181308 With Reversible Kidney Injury in a Patient With Metastatic Melanoma
- (2010) William G. Herrington et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Identification of a small-molecule inhibitor of the interaction between Survivin and Smac/DIABLO
- (2010) Tsuyoshi Oikawa et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant and platinum-based drugs
- (2010) T Iwasa et al. BRITISH JOURNAL OF CANCER
- Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
- (2010) M. Tanioka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein
- (2010) Y Shao et al. CANCER GENE THERAPY
- Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
- (2010) Akihiro Miyazaki et al. CANCER SCIENCE
- Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
- (2010) D. C. Talbot et al. CLINICAL CANCER RESEARCH
- Activation of AMP-activated Protein Kinase α1 Alleviates Endothelial Cell Apoptosis by Increasing the Expression of Anti-apoptotic Proteins Bcl-2 and Survivin
- (2010) Chao Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide
- (2010) Puja Sapra et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells
- (2009) C-T Yang et al. CANCER GENE THERAPY
- Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer
- (2009) Ichiya Honma et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Adeno-Associated Virus Harboring Fusion Gene NT4-Ant-Shepherdin Induce Cell Death in Human Lung Cancer Cells
- (2009) Tang Xiaojiang et al. CANCER INVESTIGATION
- Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
- (2009) T. Satoh et al. CLINICAL CANCER RESEARCH
- A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
- (2009) Karl D. Lewis et al. INVESTIGATIONAL NEW DRUGS
- Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer
- (2009) Giuseppe Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- DOCK 6: Combining techniques to model RNA-small molecule complexes
- (2009) P. T. Lang et al. RNA
- Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes
- (2008) Qi Fei et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines
- (2008) T. Iwasa et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
- (2008) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- A Survivin-Ran Complex Regulates Spindle Formation in Tumor Cells
- (2008) F. Xia et al. MOLECULAR AND CELLULAR BIOLOGY
- SPC3042: a proapoptotic survivin inhibitor
- (2008) J. B. Hansen et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started